Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
134.09
+3.59 (2.75%)
May 22, 2026, 2:46 PM EDT - Market open
Gilead Sciences Revenue
Gilead Sciences had revenue of $6.96B in the quarter ending March 31, 2026, with 4.39% growth. This brings the company's revenue in the last twelve months to $29.74B, up 3.48% year-over-year. In the year 2025, Gilead Sciences had annual revenue of $29.44B with 2.40% growth.
Revenue (ttm)
$29.74B
Revenue Growth
+3.48%
P/S Ratio
5.58
Revenue / Employee
$1,749,176
Employees
17,000
Market Cap
166.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.44B | 689.00M | 2.40% |
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | 22.45B | 322.00M | 1.46% |
| Dec 31, 2018 | 22.13B | -3.98B | -15.24% |
| Dec 31, 2017 | 26.11B | -4.28B | -14.09% |
| Dec 31, 2016 | 30.39B | -2.25B | -6.89% |
| Dec 31, 2015 | 32.64B | 7.75B | 31.13% |
| Dec 31, 2014 | 24.89B | 13.69B | 122.19% |
| Dec 31, 2013 | 11.20B | 1.50B | 15.46% |
| Dec 31, 2012 | 9.70B | 1.32B | 15.70% |
| Dec 31, 2011 | 8.39B | 435.97M | 5.48% |
| Dec 31, 2010 | 7.95B | 938.04M | 13.38% |
| Dec 31, 2009 | 7.01B | 1.68B | 31.40% |
| Dec 31, 2008 | 5.34B | 1.11B | 26.14% |
| Dec 31, 2007 | 4.23B | 1.20B | 39.78% |
| Dec 31, 2006 | 3.03B | 997.74M | 49.19% |
| Dec 31, 2005 | 2.03B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| AstraZeneca | 60.44B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
GILD News
- 41 minutes ago - US FDA approves Gilead's drug for deadly liver infection - Reuters
- 6 hours ago - Gilead receives positive CHMP opinion for Trodelvy in TNBC - TheFly
- 7 hours ago - Gilead Receives CHMP Positive Opinion for Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer for Patients Not Candidates for PD-(L)1 Inhibitors - Business Wire
- 21 hours ago - New ASCO and EHA 2026 Data Demonstrate Gilead and Kite's Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology - Business Wire
- 1 day ago - Gilead completes acquisition of Tubulis for $3.15B upfront - TheFly
- 1 day ago - Gilead Sciences Completes Acquisition of Tubulis Further Strengthening Oncology Portfolio - Business Wire
- 1 day ago - Gilead renews five-year collaboration with World Health Organization - TheFly
- 1 day ago - Gilead Sciences and World Health Organization Expand Collaboration to Help Eliminate Visceral Leishmaniasis, a Fatal Parasitic Disease - Business Wire